• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company

    12/22/25 8:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care
    Get the next $HIND alert in real time by email

    Vyome Board completes review of strategic alternatives for LICH, executes critical first step in building a scalable, standalone business

    Vyome Holdings, Inc. ("Vyome') (NASDAQ:HIND) announced its subsidiary, LiveChain, Inc. ("Livechain" or "LICH") (OTC Markets: LICH) has executed a binding letter of intent ("LOI") with Remus Capital, a leading AI-focused venture capital firm, that will put LiveChain in control of the Humanyze brand, intellectual property, and other know-how of Sociometric Solutions, Inc. DBA Humanyze ("Humanyze"), a rapidly emerging AI-enabled human resources data and analytics company.

    The LOI contemplates that, as consideration for the transaction, LICH shall issue shares of its common stock valued at approximately $325,000, in exchange for acquiring a senior secured convertible note between Remus and Humanyze. Through this transaction, LICH will be the senior secured creditor of Humanyze, whose note is secured by a lien in all of Humanyze's intellectual property and trade secrets.

    Born from the prestigious MIT Media Lab, Humanyze has one of the world's largest databases for employee interactions within the workplace and is working to redefine the future of work through science-backed analytics and AI-enabled insights that help large, complex companies make continuous workplace improvements that benefit both employees and the business.

    "One of our immediate objectives as the Board of Directors of Vyome was to find a way to create value from LiveChain, as we promised LiveChain and Vyome shareholders. We evaluated multiple options, but this path is the first step of a plan that could enable LiveChain to become self-sufficient financially and build a scalable independent business that could generate significant value for shareholders," commented Venkat Nelabhotla, Board member of LiveChain and CEO of Vyome. "Humanyze is attacking one of the biggest issues facing Fortune 1000 companies around the world – human capital, and the cost of developing, retaining, and rewarding people in the most cost-effective way possible."

    "Humanyze has built a compelling AI-enabled platform that breaks down critical data to give employers clear, actionable insights that optimize many companies' most valuable resource, their human capital. This optimization is even more critical in an age where humans and AI have to waltz together in the workplace. We see multiple ways for Humanyze to monetize their offerings, and the market opportunity is quite compelling," added Krishna Gupta, Chairman of Vyome.

    The LOI contemplates that the parties will enter into definitive agreements upon the terms set forth in the LOI within 30 days of the execution of the LOI and to consummate a closing within an additional 45 days, upon satisfaction of all conditions precedent as may be outlined in the definitive agreements. There can be no assurance that the transaction contemplated by the LOI is consummated.

    About Vyome Holdings, Inc.

    Vyome is building the world's premier platform spanning the US-India innovation corridor. Based in Cambridge, MA, Vyome's immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. To learn more, please visit www.vyometx.com

    Forward-Looking Statements

    Certain statements made in this press release are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "target," "believe," "expect," "will," "shall," "may," "anticipate," "estimate," "would," "positioned," "future," "forecast," "intend," "plan," "project," "outlook", and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such statements, include, but are not limited to, statements contained in this press release relating to Vyome's business strategy, Vyome's future operating results and liquidity and capital resources outlook. Forward-looking statements are based on Vyome's current expectations and assumptions regarding Vyome's business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Vyome's actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. Vyome cautions you, therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, Vyome's ability to raise capital to fund continuing operations; our ability to protect Vyome's intellectual property rights; the impact of any infringement actions or other litigation brought against Vyome; competition from other providers and products; Vyome's ability to develop and commercialize products and services; changes in government regulation; Vyome's ability to complete capital raising transactions; and other factors relating to Vyome's industry, operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause Vyome's actual results to differ may emerge from time to time, and it is not possible for Vyome to predict all of them. Vyome cannot guarantee future results, levels of activity, performance, or achievements. Vyome assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release, except as may be required under applicable securities law.

    Visit us on social media:

    Facebook

    X

    LinkedIn

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251222453959/en/

    [email protected]

    Get the next $HIND alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIND

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HIND
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

    VT-1953 topical gel significantly reduced MFW-associated severe malodor over a 14 Day period (P=0.0020) as scored by investigators. VT-1953 efficacy was significantly superior to the vehicle control (P= 0.0015). 70% of patients treated with VT-1953 vs 0% of patients treated with vehicle (control arm) reported an improvement in patient-reported outcome measure of impact of malodor on life by Day 14 (P= 0.0256). Patients treated with VT-1953 reported a clinically significant 2 point improvement in lesion pain by Day 14 (p= 0.0020) as scored using a 10-point VAS scale. No change seen in vehicle-treated arm. No treatment-emergent adverse effects were reported in this Phase 2 study.

    4/22/26 8:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

    Complete Phase 2 clinical data on the efficacy and safety of VT-1953 in MFW patients accepted for presentation at the annual meeting of the American Association for Cancer Research Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds ("MFW") at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place on April 17-22, 2026, in San Diego. Venkat Nelabhotla, CEO of Vyome, stated that, "There are currently no FDA approved

    4/6/26 8:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

    Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debt Delivered positive final Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations Independent valuation consulting firm, Destum Partners, valued VT-1953 at approximately $1 billion after a successful pivotal study Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through mid 2027, taking it up to pivotal trial interim readouts Added a new CTO, SVP of Clinical Development, and Senior Medical Advisor, bringing Big P

    3/26/26 8:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    $HIND
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Pomichter Stanley D Iii

    4 - Vyome Holdings, Inc (0001427570) (Issuer)

    11/19/25 4:10:06 PM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Pomichter Stanley D Iii

    3 - Vyome Holdings, Inc (0001427570) (Issuer)

    11/19/25 4:05:05 PM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Director Jolly Mohanjit was granted 454,456 shares (SEC Form 4)

    4 - Vyome Holdings, Inc (0001427570) (Issuer)

    11/18/25 6:45:47 PM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    $HIND
    SEC Filings

    View All

    SEC Form DEF 14A filed by Vyome Holdings Inc.

    DEF 14A - Vyome Holdings, Inc (0001427570) (Filer)

    3/31/26 6:03:52 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    SEC Form PRE 14A filed by Vyome Holdings Inc.

    PRE 14A - Vyome Holdings, Inc (0001427570) (Filer)

    3/20/26 4:56:33 PM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Vyome Holdings Inc.

    10-K - Vyome Holdings, Inc (0001427570) (Filer)

    3/18/26 6:38:57 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    $HIND
    Leadership Updates

    Live Leadership Updates

    View All

    Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program

    Dr. Bardia has led the clinical development and FDA approvals of multiple blockbuster drugs Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND), a clinical-stage healthcare holding company, today announced Dr. Aditya Bardia as Senior Medical Advisor to Vyome. In this consulting role, Dr. Bardia will guide the clinical development of Vyome's lead asset, VT-1953, for the treatment of symptoms of malignant fungating wounds (MFW), a debilitating condition in cancer patients for which approval is being targeted in 2026. "I am excited to work with Vyome team and guide the clinical development of VT-1953 for the treatment of symptoms of malignant fungating wound, a debilitating condition that can signi

    11/25/25 7:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Vyome Holdings Announces Results of Annual Shareholder Meeting

    All 3 Class I directors, formerly at MIT, are re-elected to the board until the 2028 annual meeting Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND) announced it held its annual shareholder meeting on October 28, 2025. All 3 Class I directors up for re-election – Krishna K. Gupta, Shiladitya Sengupta, and Stash Pomichter – were re-elected to serve on Vyome's board until the 2028 annual shareholder meeting, with 93% of the votes being cast in favor. "This vote of confidence from shareholders ensures that Vyome's strong, innovative DNA of MIT alums remains intact for years to come. None of the Independent board members is taking any cash compensation or any new equity grants (other than grants

    11/4/25 9:04:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

    Dr. Richard Fahrner and Dr. Tamara Agajanov add expertise in accelerated approvals Vyome Holdings, Inc. (NASDAQ:HIND), a clinical-stage healthcare holding company, today announced the appointment of Dr. Richard Fahrner as Chief Technology Officer and Dr. Tamara Agajanov, MD, as Senior Vice President – Clinical Development. Dr. Fahrner brings to Vyome over 25 years of experience in drug development, recently serving as the head of pharmaceutical development at Ra Pharmaceuticals, which was acquired by UCB in a $2.5B deal. He also served as a research and development leader at Catabasis, Pfizer, Sanofi and Gilead. Dr. Fahrner has been involved with the development of more than 17 approved

    9/9/25 8:30:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    $HIND
    Financials

    Live finance-specific insights

    View All

    Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

    Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debt Delivered positive final Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations Independent valuation consulting firm, Destum Partners, valued VT-1953 at approximately $1 billion after a successful pivotal study Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through mid 2027, taking it up to pivotal trial interim readouts Added a new CTO, SVP of Clinical Development, and Senior Medical Advisor, bringing Big P

    3/26/26 8:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

    (Quarter Ended September 30, 2025) Completed a streamlined Nasdaq listing, with a 100% common stock capital structure Delivered encouraging interim Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations. Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through 2026, inclusive of clinical trials. Added a new CTO and SVP of Clinical Development, bringing Big Pharma backgrounds, deep drug-development expertise, and experience across multiple FDA-approved therapies. Launched AI strategy with the acquisition of MIT startup Oculo Vyome Holdings, I

    11/18/25 7:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Vyome Holdings Acquires MIT AI Spinout Oculo Health

    Launches business unit to create AI psychiatrist focused on reducing inflammation Vyome remains fully funded through 2026 to unlock value from core assets Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced it has acquired substantially all of the assets of Oculo, Inc., an AI startup launched at the Massachusetts Institute of Technology ("MIT"). Concurrent with this transaction, Vyome has launched a new business unit focused on using AI to tackle inflammation. This new business unit will leverage Oculo's assets to develop an AI psychiatrist trained on data from both the US and India, and will be overseen by a newly-formed Vyome Board of Dire

    9/29/25 7:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care